(Q52172787)

26 April 2018

title

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. (English)

1 reference

26 April 2018

1 reference

1 reference

A Labelle

1

1 reference

26 April 2018

L J Boulay

series ordinal

2

1 reference

26 April 2018

Y D Lapierre

series ordinal

3

1 reference

26 April 2018

language of work or name

English

0 references

publication date

1 November 1999

1 reference

26 April 2018

Canadian Journal of Psychiatry

published in

1 reference

26 April 2018

volume

44

1 reference

26 April 2018

issue

9

1 reference

26 April 2018

page(s)

887-892

1 reference

26 April 2018

Another view of active-controlled trials

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400904

The use of placebos in clinical trials for acute schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400904

The continuing unethical use of placebo controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400904

Placebo effects in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400904

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400904

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400904

10.1177/070674379904400904

21 January 2018

Identifiers

DOI

1 reference

26 April 2018

1 reference

26 April 2018